NYSE: UHTUniversal Health Realty Income Trust Stock
$38.16-0.22 (-0.57%)
Updated Apr 21, 2025
UHT Price
$38.16
Fair Value Price
N/A
Market Cap
$528.54M
52 Week Low
$33.36
52 Week High
$47.30
P/E
27.45x
P/B
2.94x
P/S
5.19x
PEG
260.6x
Dividend Yield
7.68%
Revenue
$99.01M
Earnings
$19.23M
Gross Margin
100%
Operating Margin
38.46%
Profit Margin
19.4%
Debt to Equity
2.24
Operating Cash Flow
$47M
Beta
0.74
Next Earnings
Apr 22, 2025
Ex-Dividend
N/A
Next Dividend
N/A
UHT Overview
Universal Health Realty Income Trust is a real estate investment trust (REIT) that invests in acute care hospitals, rehabilitation hospitals, sub-acute care facilities, medical/office buildings, free-standing emergency departments and childcare centers. The company has interests in 71 properties in 20 states. The company was formed in 1976 and is headquartered in King Of Prussia, PA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine UHT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Facility REIT
Industry Rating
C
UHT
Ranked#8 of 16
Ranked#8 of 16
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $28.06 | C | |
| $66.81 | C | |
| $37.85 | C |
Be the first to know about important UHT news, forecast changes, insider trades & much more!
UHT News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how UHT scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
UHT ($38.16) is trading above its intrinsic value of $7.60, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
UHT is poor value based on its earnings relative to its share price (27.45x), compared to the US market average (27.14x)
P/E vs Market Valuation
UHT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more UHT due diligence checks available for Premium users.
Valuation
UHT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
27.45x
Industry
106.77x
Market
27.14x
UHT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
UHT is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
UHT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.94x
Industry
2.21x
UHT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
UHT price to earnings growth (PEG)
For valuing profitable companies with growth potential
UHT is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
UHT's financial health
Profit margin
Revenue
$24.6M
Net Income
$4.7M
Profit Margin
18.9%
UHT's Earnings (EBIT) of $38.08M... subscribe to Premium to read more.
Interest Coverage Financials
UHT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$580.9M
Liabilities
$401.3M
Debt to equity
2.24
UHT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
UHT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$13.2M
Investing
-$2.7M
Financing
-$9.7M
UHT's operating cash flow ($46.91M)... subscribe to Premium to read more.
Debt Coverage Financials
UHT vs Healthcare Facility REIT Stocks
Universal Health Realty Income Trust Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.